EcoDrugPlus

Matrix Metallopeptidase 8

Ensembl ID : ENSPSNG00000011640
Gene Symbol: MMP8
1 Cross references
111 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSPSNG00000014125
Gene Symbol: MMP9
3 Cross references
214 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSPSNG00000010195
Gene Symbol: MTOR
3 Cross references
214 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSPSNG00000009502
Gene Symbol: MC1R
1 Cross references
159 Possible Orthologues:

Melanocortin 3 Receptor

Ensembl ID : ENSPSNG00000019606
Gene Symbol: MC3R
1 Cross references
138 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSPSNG00000020361
Gene Symbol: MC4R
1 Cross references
121 Possible Orthologues:

Melatonin Receptor 1b

Ensembl ID : ENSPSNG00000014997
Gene Symbol: MTNR1B
1 Cross references
107 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSPSNG00000018017
Gene Symbol: MME
3 Cross references
234 Possible Orthologues:

Methionyl Aminopeptidase 2

Ensembl ID : ENSPSNG00000013429
Gene Symbol: METAP2
3 Cross references
213 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSPSNG00000013290
Gene Symbol: MAPK1
3 Cross references
213 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSPSNG00000003815
Gene Symbol: MAPK10
3 Cross references
147 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSPSNG00000016662
Gene Symbol: MAPK11
1 Cross references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).